Cardio Diagnostics (CDIO)

• Market cap: $5.8M
• 1 day: -7.11%
• 5 days: 3.7%
• 1 month: 7.1%
• 3 months: -63.5%
• 6 months: -46.3%
• Year to date: -30.99%
• 1 year: -56.64%
• 5 years: -99.33%
• 10 years: -99.33%
• Sector: Healthcare
• Industry: Biotechnology

About: Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.

Employees: 17